Telix Pharmaceuticals

Telix Pharmaceuticals announced the first patient dosed in a Phase II trial of TLX250-CDx (89Zr-girentuximab) for recurrent clear cell renal cell carcinoma (ccRCC) post-surgery, comparing its diagnostic performance to conventional imaging. The Phase III ZIRCON trial showed TLX250-CDx's high sensitivity (86%) and specificity (87%) for ccRCC detection, with an expanded access program in the U.S., named patient programs in Europe, and a special access scheme in Australia.

WuXi AppTec’s Dr Dave Madge predicts peptide-based radiotherapeutics could surpass antibody-based counterparts due to advantages like tissue penetration and low toxicity. Despite only two antibody-based radiopharmaceuticals being FDA-approved, the radiopharmaceutical space has seen significant deals, with theranostic radiopharmaceuticals combining diagnostics and therapy gaining traction. WuXi’s expansion in peptide manufacturing aims to meet global demand, but potential restrictions from the US BIOSECURE Act pose a challenge.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech and Merck. Promising drugs like Atezolizumab and ADI-270 are under various clinical trial phases, with recent FDA Fast Track designations for ADI-270 in metastatic RCC.

DelveInsight's 'Renal Cancer Pipeline Insight 2024' report highlights a robust pipeline with 70+ companies developing 75+ therapies, including key players like Genentech, Allogene Therapeutics, and Merck & Co. Inc. Promising therapies such as Atezolizumab and ALLO-316 are under various clinical trial phases, with recent FDA Fast Track designations and IND approvals for novel drugs like ADI-270 and AB-2100.

Zr-89 girentuximab PET-CT imaging accurately detects clear cell RCC with sensitivity 85.5% and specificity 87.0%, suggesting a favorable safety profile and potential practice change in RCC detection.